Cargando…

Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib

We report a case of 43-year-old woman diagnosed with essential thrombocythemia in 1992. She was diagnosed with secondary myelofibrosis in 2011. Later, she suffered mild dyspnea, which gradually worsened. She was admitted to our hospital to evaluate the cause in 2014. Chest computed tomography showed...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Ayumi, Hamaguchi, Shunichi, Suzuki, Ritsuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844769/
https://www.ncbi.nlm.nih.gov/pubmed/35198370
http://dx.doi.org/10.1016/j.lrr.2022.100290
_version_ 1784651540710031360
author Fujimoto, Ayumi
Hamaguchi, Shunichi
Suzuki, Ritsuro
author_facet Fujimoto, Ayumi
Hamaguchi, Shunichi
Suzuki, Ritsuro
author_sort Fujimoto, Ayumi
collection PubMed
description We report a case of 43-year-old woman diagnosed with essential thrombocythemia in 1992. She was diagnosed with secondary myelofibrosis in 2011. Later, she suffered mild dyspnea, which gradually worsened. She was admitted to our hospital to evaluate the cause in 2014. Chest computed tomography showed ground-glass opacity (GGO) in the lungs. A lung biopsy revealed various hematopoietic cells, including abnormal megakaryocytes, infiltrating the alveolar septum, suggesting pulmonary extramedullary hematopoiesis. She was successfully treated by ruxolitinib and her disease is well controlled for more than 7 years. To keep this phenomenon in mind when see the patients with dyspnea is important.
format Online
Article
Text
id pubmed-8844769
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88447692022-02-22 Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib Fujimoto, Ayumi Hamaguchi, Shunichi Suzuki, Ritsuro Leuk Res Rep Article We report a case of 43-year-old woman diagnosed with essential thrombocythemia in 1992. She was diagnosed with secondary myelofibrosis in 2011. Later, she suffered mild dyspnea, which gradually worsened. She was admitted to our hospital to evaluate the cause in 2014. Chest computed tomography showed ground-glass opacity (GGO) in the lungs. A lung biopsy revealed various hematopoietic cells, including abnormal megakaryocytes, infiltrating the alveolar septum, suggesting pulmonary extramedullary hematopoiesis. She was successfully treated by ruxolitinib and her disease is well controlled for more than 7 years. To keep this phenomenon in mind when see the patients with dyspnea is important. Elsevier 2022-02-07 /pmc/articles/PMC8844769/ /pubmed/35198370 http://dx.doi.org/10.1016/j.lrr.2022.100290 Text en © 2022 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fujimoto, Ayumi
Hamaguchi, Shunichi
Suzuki, Ritsuro
Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib
title Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib
title_full Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib
title_fullStr Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib
title_full_unstemmed Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib
title_short Case of Pulmonary Extramedullary Hematopoiesis Responding to Ruxolitinib
title_sort case of pulmonary extramedullary hematopoiesis responding to ruxolitinib
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844769/
https://www.ncbi.nlm.nih.gov/pubmed/35198370
http://dx.doi.org/10.1016/j.lrr.2022.100290
work_keys_str_mv AT fujimotoayumi caseofpulmonaryextramedullaryhematopoiesisrespondingtoruxolitinib
AT hamaguchishunichi caseofpulmonaryextramedullaryhematopoiesisrespondingtoruxolitinib
AT suzukiritsuro caseofpulmonaryextramedullaryhematopoiesisrespondingtoruxolitinib